Rhumbline Advisers Buys 3,136 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Rhumbline Advisers raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,673 shares of the medical equipment provider’s stock after buying an additional 3,136 shares during the period. Rhumbline Advisers’ holdings in Lantheus were worth $19,026,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the third quarter valued at $25,000. Signaturefd LLC boosted its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares in the last quarter. World Investment Advisors LLC bought a new stake in Lantheus in the 3rd quarter worth approximately $60,000. Finally, RiverPark Advisors LLC purchased a new stake in Lantheus in the third quarter worth approximately $74,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $78.23 on Friday. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89. The stock has a market capitalization of $5.44 billion, a PE ratio of 13.02 and a beta of 0.44. The business’s 50-day moving average is $90.31 and its 200 day moving average is $97.06.

Analyst Upgrades and Downgrades

Several research analysts have commented on LNTH shares. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.